Episodes

  • 10: Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

    10: Clinical Approaches for Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
    May 1 2026
    This episode reviews treatment intensification in metastatic castration-sensitive prostate cancer, focusing on why ADT plus an ARPI is the current backbone of care, what barriers still limit its use, and how clinicians think about triplet therapy, de-intensification, frail patients, and emerging biomarker-driven options such as PARP inhibitors.
    Show More Show Less
    34 mins
  • 9: Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer

    9: Indirect Trial Comparisons in Metastatic Castration-Sensitive Prostate Cancer
    May 1 2026
    This episode examines how indirect trial comparisons can help guide ARPI selection in metastatic castration-sensitive prostate cancer when head-to-head studies are unavailable, while emphasizing the importance of patient-specific factors, tolerability, and clinical judgment.
    Show More Show Less
    34 mins
  • 8: Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer

    8: Personalizing Long-Term Treatment of Metastatic Castration-Sensitive Prostate Cancer
    May 1 2026
    This episode explores how long-term management of metastatic castration-sensitive prostate cancer is increasingly shaped by personalized treatment planning that balances disease burden, patient fitness, quality of life, and shared decision-making.
    Show More Show Less
    33 mins
  • 7: Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic

    7: Managing Fatigue with ARPIs in Metastatic Castration-Sensitive Prostate Cancer in the Clinic
    May 1 2026
    This series explores how fatigue and other treatment-related adverse events influence quality of life and treatment persistence in metastatic castration-sensitive prostate cancer, with a focus on practical strategies for assessment, management, and supportive care in patients receiving ADT and ARPI-based therapy.
    Show More Show Less
    31 mins
  • 12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer

    12: Monotherapies for Treatment of High-Risk Biochemical Recurrent Prostate Cancer
    Apr 1 2026
    The faculty discusses how ARPI monotherapy may fit into the management of high-risk biochemically recurrent prostate cancer, with a focus on patient selection, trade-offs of monotherapy versus combination therapy, and practical counseling around efficacy, quality of life, and adverse events. The conversation also explores emerging questions around biomarkers, PARP inhibitors, treatment intensification, and how monotherapy may evolve as a therapeutic option in select patients.
    Show More Show Less
    29 mins
  • 11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer

    11: Treatment Strategies with Androgen Receptor Pathway Inhibitors in Castration-Sensitive Prostate Cancer
    Apr 1 2026
    The faculty discuss how androgen receptor pathway inhibitor–based strategies are reshaping the management of high-risk biochemical recurrence, with an emphasis on risk stratification, imaging, and patient selection for systemic therapy. The conversation also explores how long-term clinical evidence, treatment suspension, and emerging study designs are informing more individualized treatment decisions in practice.
    Show More Show Less
    35 mins
  • 7: Test File

    7: Test File
    Mar 18 2026
    33 mins
  • 6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice

    6: Expanding Options in mHSPC: What the Latest FDA Approval Means for Clinical Practice
    Dec 3 2025
    Panelists discuss how the recent FDA approval of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC) expands treatment options, offering improved tolerability with lower fatigue rates and fewer central nervous system adverse effects than other androgen pathway inhibitors, while exploring considerations for patient selection, trial design interpretation, and the evolving role of real-world evidence in clinical decision-making.
    Show More Show Less
    39 mins